Olivia Brayer Saunders Analyst Performance

Analyst at Cantor Fitzgerald

Olivia Brayer Saunders is a stock analyst at Cantor Fitzgerald focused in the healthcare sector, covering 26 publicly traded companies. Over the past year, Olivia Brayer Saunders has issued 31 stock ratings, including buy and hold recommendations. While full access to Olivia Brayer Saunders' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Olivia Brayer Saunders' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
61 Last 4 Years
Buy Recommendations
88.52% 54 Buy Ratings
Companies Covered
26 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy3.3%2 ratings
Buy85.2%52 ratings
Hold11.5%7 ratings
Sell0.0%0 ratings

Out of 61 total stock ratings issued by Olivia Brayer Saunders at Cantor Fitzgerald, the majority (85.2%) have been Buy recommendations, followed by 11.5% Hold and 3.3% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.3% of companies on NASDAQ
24 companies
NYSEAMERICAN
3.8% of companies on NYSEAMERICAN
1 company
NYSE
3.8% of companies on NYSE
1 company

Olivia Brayer Saunders, an analyst at Cantor Fitzgerald, currently covers 26 companies listed on NASDAQ, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
24 companies
92.3%
Miscellaneous
2 companies
7.7%

Olivia Brayer Saunders of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
16 companies
61.5%
PHARMACEUTICALS
8 companies
30.8%
Miscellaneous
2 companies
7.7%

Olivia Brayer Saunders' Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Quince Therapeutics, Inc. stock logo
IRLA
Quince Therapeutics
11/19/2026Reiterated Rating$40.59$70.00Overweight
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
11/17/2026Lower Price Target$159.73$205.00Neutral
MannKind Corporation stock logo
MNKD
MannKind
11/6/2026Boost Price Target$3.76$10.00Overweight
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
11/3/2026Reiterated Rating$54.29Overweight
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
10/26/2026Reiterated Rating$590.12$850.00Overweight
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
10/20/2026Initiated Coverage$0.50$2.00Overweight
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
10/20/2026Reiterated Rating$54.67$86.00Overweight
MannKind Corporation stock logo
MNKD
MannKind
10/20/2026Reiterated Rating$3.09$8.00Overweight
Braveheart Bio, Inc. stock logo
BRVE
Braveheart Bio
10/20/2026Reiterated Rating$19.21$40.00Overweight
Omeros Corporation stock logo
OMER
Omeros
10/14/2026Reiterated Rating$18.88$22.00Overweight
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
10/1/2026Reiterated Rating$541.89Overweight
Omeros Corporation stock logo
OMER
Omeros
9/22/2026Upgrade$18.49$22.00Overweight
MannKind Corporation stock logo
MNKD
MannKind
9/11/2026Reiterated Rating$3.79$8.00Overweight
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
9/10/2026Reiterated Rating$2.06Overweight
Braveheart Bio, Inc. stock logo
BRVE
Braveheart Bio
8/31/2026Initiated Coverage$27.44$40.00Overweight
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
8/20/2026Initiated Coverage$1.08$3.00Overweight
Quince Therapeutics, Inc. stock logo
IRLA
Quince Therapeutics
8/18/2026Reiterated Rating$34.12$70.00Overweight
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
7/29/2026Reiterated Rating$15.80$35.00Overweight
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
6/24/2026Reiterated Rating$13.64$35.00Overweight
Quince Therapeutics, Inc. stock logo
IRLA
Quince Therapeutics
6/23/2026Initiated Coverage$18.55$80.00Overweight
Quince Therapeutics, Inc. stock logo
IRLA
Quince Therapeutics
6/23/2026Initiated Coverage$19.36$80.00Overweight
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
5/21/2026Initiated Coverage$2.31$4.00Overweight
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
5/21/2026Initiated Coverage$2.36$4.00Overweight
Pelthos Therapeutics Inc. stock logo
PTHS
Pelthos Therapeutics
4/1/2026Initiated Coverage$21.01$50.00Overweight
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3/23/2026Reiterated Rating$0.42Neutral
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
3/17/2026Initiated Coverage$13.98$35.00Overweight
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
3/12/2026Boost Price Target$535.20$625.00Overweight
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2/4/2026Boost Price Target$5.78$10.00Overweight
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
12/17/2025Reiterated Rating$6.93Overweight
Insmed, Inc. stock logo
INSM
Insmed
12/16/2025Boost Price Target$196.92$230.00Overweight
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
12/11/2025Initiated Coverage$1.48$4.00Overweight
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10/30/2025Lower Price Target$4.51$11.00Overweight
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
9/22/2025Initiated Coverage$1.98$6.00Overweight
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
9/22/2025Initiated Coverage$2.06$6.00Overweight
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
9/11/2025Reiterated Rating$3.11Overweight
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
9/10/2025Boost Price Target$403.80$525.00Overweight
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
6/2/2025Initiated Coverage$316.34$405.00Overweight
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
5/14/2025Reiterated Rating$3.92$13.00Overweight
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
5/13/2025Upgrade$3.88Strong-Buy
Mesoblast Limited stock logo
MESO
Mesoblast
3/31/2025Upgrade$11.82Strong-Buy
My $247 scanner for $7 (Ad)

Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel

Get the Instant Scanner for $7 in the Black Friday sale today.
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2/20/2025Reiterated Rating$68.49$90.00Overweight
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2/11/2025Reiterated Rating$460.76$480.00Overweight
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2/4/2025Boost Price Target$60.03$55.00Neutral
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
1/31/2025Reiterated Rating$462.91$480.00Overweight
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
1/24/2025Reiterated Rating$439.97$480.00Overweight